Cancer Biology

癌症生物学计划的重点是机制和信号通路的研究 参与了细胞的恶性转化。目标是促进对以下方面的基本理解 癌症发病机制，并将基础科学发现转化为临床领域，以改善 癌症患者的预后。该方案包括三个主要专题小组：1) 肿瘤发生的机制和途径；2)细胞周期、细胞骨架和基因组稳定性；3) 上皮性肿瘤(包括皮肤癌、前列腺癌和肺癌)。调查的重点是 癌基因和抑癌基因的机制研究，细胞分裂的控制，基因组学 稳定性和DNA损伤检查点，以及血液学中特定疾病的兴趣 恶性肿瘤、皮肤癌、前列腺癌和肺癌。这40名调查人员代表两个不同的学校( 医学院和人文科学学院)，16个系和5个司 医学部。40名调查人员的研究活动得到了73名同行评议的支持， 由调查员发起的赠款(R01和其他)，以及五个T32培训奖。NCI总数 支持金额为430万美元，其他NIH支持金额为720万美元，非NIH支持金额为320万美元。自.以来 2005年，项目研究人员在同行评议中发表了400多篇与癌症生物学相关的手稿 日记。癌症中心将继续在协助翻译 本计划的基本科学发现转化为新的临床诊断和治疗方法 癌症患者的治疗。

The Program in Cancer Biology is focused on investigations into mechanisms and signaling pathways involved in the malignant transformation of cells. The goals are to advance basic understanding of cancer pathogenesis and to translate basic science discoveries into the clinical arena to improve the outcome of patients with cancer. The Program encompasses three major thematic groups: 1) Mechanisms and Pathways of Oncogenesis; 2) Cell Cycle, Cytoskeleton and Genomic Stability; and 3) Epithelial Neoplasia (including skin, prostate and lung cancer subgroups). Investigations are focused on mechanistic studies of oncogenes and tumor suppressor genes, the control of cell division, genomic stability and DNA damage checkpoints, as well as disease-specific interests in hematologic malignancies, skin, prostate and lung cancers. The 40 investigators represent two different schools (the School of Medicine and the School of Humanities & Sciences), 16 Departments, and five Divisions within the Department of Medicine. The research activities of the 40 investigators are supported by 73 peer-reviewed, investigator-initiated grants (R01s and others), and five T32 training awards. Total NCI support is $4.3 million, other NIH support is $7.2 million, and non-NIH support is $3.2 million. Since 2005, program investigators have published over 400 manuscripts relevant to cancer biology in peer-reviewed journals. The Cancer Center will continue to be invaluable in assisting with the translation of the basic science findings from this Program into new clinical approaches for the diagnosis and treatment of patients with cancer.